Familial Renal Glucosuria and Potential Pharmacogenetic Impact on Sodium-Glucose Cotransporter-2 Inhibitors
Kidney360 · 2025-04 · 6 (4) · 521-530
DOI: 10.34067/kid.0000000621 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, online erschienen am 16.10.2024. Verfasst von Patrick Allaire und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Precision Medicine Research, Marshfield Clinic Health System , Marshfield, Wisconsin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIGMS NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
Key Points A significant knowledge gap exists in SLC5A2 's role in familial renal glycosuria and sodium-glucose cotransporter-2 inhibitors' efficacy. Two percent of individuals in the All-of-Us cohort harbor rare genetic variants in SLC5A2 , potentially increasing the risk of familial renal glycosuria. Our trial suggests differential responses to sodium-glucose cotransporter-2 inhibitors in individuals with rare SLC5A2 alleles compared with wild types.
Background
Renal glucosuria is a rare inheritable trait caused by loss-of-function variants in the gene that encodes sodium-glucose cotransporter-2 (SGLT2) ( i.e ., SLC5A2 ). The genetics of renal glucosuria is poorly understood, and even less is known on how loss-of-function variants in SLC5A2 may affect response to SGLT2 inhibitors, a new class of medication gaining popularity to treat diabetes by artificially inducing glucosuria.
Methods
We used two biobanks that link genomic with electronic health record data to study the genetics of renal glucosuria. This included 245,394 participants enrolled in the All of Us Research Program and 11,011 enrolled in Marshfield Clinic's Personalized Research Project (PMRP). Association studies in All of Us and PMRP identified ten variants that reached an experiment-wise Bonferroni threshold in either cohort, of which nine were novel. PMRP was further used as a recruitment source for a prospective SGLT2 pharmacogenetic trial. During a glucose tolerance test, the trial measured urine glucose concentrations in 15 SLC5A2 variant–positive individuals and 15 matched wild types with and without an SGLT2 inhibitor.
Results
This trial demonstrated that carriers of SLC5A2 risk variants may be more sensitive to SGLT2 inhibitors compared with wild types ( P = 0.075). On the basis of population data, 2% of an ethnically diverse population carried rare variants in SLC5A2 and are at risk of renal glucosuria.
Conclusions
As a result, 2% of individuals being treated with SGLT2 inhibitors may respond differently to this new class of medication compared with the general population, suggesting that a larger investigation into SLC5A2 variants and SGLT2 inhibitors is needed.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Precision Medicine Research, Marshfield Clinic Health System , Marshfield, Wisconsin.
ORCID-Profile: Patrick Allaire, Jamie Fox, Rachel Gabor
Förderung
- NCATS NIH HHS
- NIGMS NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Allaire, P., Fox, J., Kitchner, T., Gabor, R., Folz, C., Bettadahalli, S., & Hebbring, S. (2025). Familial Renal Glucosuria and Potential Pharmacogenetic Impact on Sodium-Glucose Cotransporter-2 Inhibitors. Kidney360, 6(4), 521-530. https://doi.org/10.34067/kid.0000000621
Vancouver
Allaire P, Fox J, Kitchner T, Gabor R, Folz C, Bettadahalli S, et al. Familial Renal Glucosuria and Potential Pharmacogenetic Impact on Sodium-Glucose Cotransporter-2 Inhibitors. Kidney360. 2025;6(4):521-530. doi:10.34067/kid.0000000621
BibTeX
@article{Allaire2025,
author = {Allaire, Patrick and Fox, Jamie and Kitchner, Terrie and Gabor, Rachel and Folz, Connie and Bettadahalli, Shankar and Hebbring, Scott},
title = {Familial Renal Glucosuria and Potential Pharmacogenetic Impact on Sodium-Glucose Cotransporter-2 Inhibitors},
journal = {Kidney360},
year = {2025},
volume = {6},
number = {4},
pages = {521--530},
doi = {10.34067/kid.0000000621}
}
EUVIMED